'Vabysmo,' the first bispecific antibody for the treatment of ophthalmologic disease, is under review for expanded indication for retinal vein occlusion (RVO) in South Korea.

According to industry sources, Roche Korea has applied for expanded approval of Vabysmo (faricimab) from the Ministry of Food and Drug Safety (MFDS). The drug received approval for the RVO indication from the U.S. Food and Drug Administration (FDA) last October.

Vabysmo is a treatment for macular degeneration that draws attention for significantly extending the administration interval compared to 'Eylea (aflibercept),' which has been the standard therapy.

In South Korea, Vabysmo's prescription became